Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsGold Coast Health Plan KEBILIDI Coverage | OpenPay…
    Ask Trek AI about this page
    CurrentGold Coast Health PlanPolicy N/A

    KEBILIDI Coverage for Aromatic L-Amino Acid Decarboxylase Deficiency

    Customize your policy alerts

    Sign up for all goldcoasthealthplan policy alerts

    Know when goldcoasthealthplan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and Part B coverage for physician-administered KEBILIDI (eladocagene exuparvovec-tneq), an intraputaminal gene therapy for adult and pediatric patients with aromatic L-amino acid decarboxylase deficiency, including diagnostic, clinical, provider, age, dosing, safety, and one-time lifetime-use requirements.

    Policy Summary
    PayerGold Coast Health Plan
    PolicyKEBILIDI Coverage for Aromatic L-Amino Acid Decarboxylase Deficiency
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateNovember 13, 2025
    Last ReviewNov 13, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming AADC deficiency, clinical eligibility, specialist involvement, skull maturity, antibody testing, and dose limits.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    1 doseMaximum dose per lifetime
    1.8 × 10^11 vgMaximum treatment dose
    ≥16 monthsMinimum patient age
    2 of 3

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Required diagnostic tests
    <1200-fold or OD >1Baseline antibody result
    AADC deficiencyCovered indication

    Coverage Criteria

    Initial KEBILIDI Coverage Criteria

    Covered when ALL of the following are met:

    Administration: KEBILIDI is administered by a physician via intraputaminal infusion using stereotactic surgery.

    AADC diagnosis

    • Core diagnostic tests

      • CSF testing: Positive CSF neurotransmitter metabolite panel.
      • Genetic testing: Positive single-gene or genetic-panel testing.
      • Enzyme testing: Positive plasma enzyme assay.
    Clinical impairment: The patient has persistent neurological defects secondary to AADC deficiency despite standard medical therapy.
    Specialist prescribing: KEBILIDI is prescribed by, or in consultation with, a neurologist and/or geneticist.
    Age and skull maturity: The patient is at least 16 months old and has achieved skull maturity documented by neuroimaging.Age ≥16 months
    Baseline antibody testing: Baseline laboratory testing demonstrates an anti-AAV2 neutralizing antibody titer below 1200-fold or ELISA optical density greater than 1.<1200-fold or OD >1
    Dose: The dose does not exceed 1.8 × 10^11 vector genomes or 0.32 mL total volume.1.8 × 10^11 vector genomes; 0.32 mL

    Coverage Duration

    Approval is limited to one treatment:

    One-time therapy: Approval is for one dose only, with a maximum of one dose per lifetime.1 dose per lifetime

    Dose will be approved according to FDA-approved labeling or accepted standards of medical practice.

    Coverage requires documentation that the patient has achieved skull maturity as assessed by neuroimaging. Patients who have not achieved skull maturity are not eligible for coverage.

    Use of KEBILIDI in patients younger than 16 months is not supported by this policy. Covered patients must be at least 16 months old and have skull maturity confirmed by neuroimaging.

    Coding and Policy Parameters

    Covered NDC CodesNDCCovered
    52856-601-0110-digit NDC package (carton)
    52855-601-1110-digit NDC container (vial)
    52856-0601-01NDC package (carton)
    52855-0601-11NDC container (vial)
    Covered HCPCS CodesHCPCSCovered
    C9399Unclassified drugs or biologicals
    J3590Unclassified biologics
    Covered CPT CodesCPTCovered
    64999Unlisted procedure, nervous system
    Maximum Dose
    Maximum vector genomes1.8 × 10^11 vector genomes
    Maximum total volume0.32 mL total volume
    Dose requirementThe dose must not exceed either the vector-genome or total-volume limit.
    Minimum Age
    Minimum ageAt least 16 months old
    Age restrictionKEBILIDI has not been studied in patients younger than 16 months.
    Related eligibility requirement

    Provider Requirements and Denial Risks

    Prior Authorization

    KEBILIDI Prior Authorization Required

    Prior authorization is required for KEBILIDI (eladocagene exuparvovec-tneq) for the treatment of AADC deficiency. Submit documentation confirming the FDA-approved indication and that all coverage criteria are met before administration.

    • Physician-administered intraputaminal infusion via stereotactic surgery.
    • Document the AADC deficiency diagnosis and required clinical eligibility criteria.
    Documentation Required

    Failure of Standard Medical Therapy

    Document that the patient continues to experience persistent neurological defects secondary to AADC deficiency despite standard medical therapy.

    • Include the relevant prior treatment history and the ongoing neurological deficits.
    • Standard treatment recommendations may include selective dopamine agonists, MAO inhibitors, pyridoxine, and additional symptomatic agents as clinically appropriate.

    Background

    KEBILIDI (eladocagene exuparvovec-tneq) is an adeno-associated virus vector-based gene therapy that expresses the human aromatic L-amino acid decarboxylase enzyme. It is used for patients with aromatic L-amino acid decarboxylase (AADC) deficiency and is administered by a physician through intraputaminal infusion using stereotactic surgery.

    Definitions

    KEBILIDI
    Therapy typeAdeno-associated virus (AAV) vector-based gene therapy
    Therapeutic expressionExpresses the human aromatic L-amino acid decarboxylase enzyme (AADC)
    AdministrationAdministered by intraputaminal infusion
    Aromatic L-Amino Acid Decarboxylase Deficiency
    Disease definitionAADC deficiency is a disorder involving deficient aromatic L-amino acid decarboxylase activity.
    Diagnostic supportDiagnosis is supported by biochemical, genetic, and enzyme testing.
    Genetic finding

    Initial Therapy Eligibility

    Initial Therapy Eligibility

    Initial treatment is covered when all policy criteria are met:

    Administration: KEBILIDI is administered by a physician via intraputaminal infusion using stereotactic surgery.
    Diagnosis: AADC deficiency is confirmed by positive results from at least two of three core diagnostic tests.2 of 3 positive tests

    The core tests are the CSF neurotransmitter metabolite panel, single-gene or genetic-panel testing, and plasma enzyme assay.

    Persistent neurological defects remain despite standard medical therapy.
    Specialist: KEBILIDI is prescribed by or administered in consultation with a neurologist and/or geneticist.

    Continuation Therapy

    No Repeat Dosing

    No continuation therapy is authorized:

    Lifetime limitation: KEBILIDI is a one-time treatment and may not be repeated after the approved dose.Maximum 1 dose per lifetime

    Step Therapy Requirements

    StepRequired prior therapyCoverage condition
    1Prior standard medical therapy, including clinically appropriate treatment with selective dopamine agonists, MAO inhibitors, and pyridoxine; additional symptomatic agents may include anticholinergics, melatonin, benzodiazepines, and alpha-adrenoreceptor blockers.Persistent neurological defects secondary to AADC deficiency despite standard medical therapy.

    Quantity and Dose Limits

    KEBILIDI Quantity Limit
    Lifetime quantity limitMaximum one dose per lifetime
    Approval durationOne-time approval only
    Repeat dosingKEBILIDI may not be repeated after the approved dose.
    KEBILIDI Maximum Dose
    Maximum dose1.8 × 10^11 vector genomes
    Maximum total volume0.32 mL total volume
    Dose limitThe prescribed dose must not exceed 1.8 × 10^11 vector genomes or 0.32 mL total volume.

    Site and Method of Administration

    Billing Rule

    Administer KEBILIDI in the required setting

    KEBILIDI must be administered by a physician through intraputaminal infusion via stereotactic surgery in the hospital outpatient setting.

    • Physician-administered intraputaminal infusion
    • Stereotactic surgery
    • Hospital outpatient setting
    Policy Summary
    PayerGold Coast Health Plan
    PolicyKEBILIDI Coverage for Aromatic L-Amino Acid Decarboxylase Deficiency
    Policy CodePolicy N/A
    Change TypeNo material clinical or coverage change
    Effective DateNovember 13, 2025
    Last ReviewNov 13, 2025
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation confirming AADC deficiency, clinical eligibility, specialist involvement, skull maturity, antibody testing, and dose limits.
    SourceLink
    On This Page
    Coverage CriteriaCoding and Policy ParametersProvider Requirements and Denial RisksBackgroundDefinitionsInitial Therapy EligibilityContinuation TherapyStep Therapy RequirementsQuantity and Dose LimitsSite and Method of Administration
    Skull maturity must be confirmed by neuroimaging.
    Anti-AAV2 Neutralizing Antibody Requirement
    Required testBaseline anti-AAV2 neutralizing antibody testing is required.
    Acceptable titer resultBelow 1200-fold
    Alternative laboratory resultELISA optical density (OD) greater than 1
    Diagnostic Confirmation
    Confirmation thresholdPositive results from 2 of 3 core diagnostic tests
    Core testsCSF neurotransmitter metabolite panel; single-gene or genetic-panel testing; and plasma enzyme assay
    Additional diagnostic requirementGenetic testing should be completed to confirm AADC deficiency.

    Unsupported block type: documentation

    Documentation Required

    Persistent Neurological Impairment

    Provide documentation of persistent neurological impairment attributable to AADC deficiency.

    • Examples of relevant manifestations include movement disorders, developmental delay, or abnormal tone regulation.
    Documentation Required

    Specialist Involvement Required

    KEBILIDI must be prescribed by, or administered in consultation with, a neurologist and/or geneticist.

    • Document the specialist's involvement in prescribing or consultation.
    Documentation Required

    Age and Skull Maturity Documentation

    Document that the patient is at least 16 months old and has achieved skull maturity confirmed by neuroimaging.

    • KEBILIDI has not been studied in patients younger than 16 months or 65 years and older.
    • Include the neuroimaging confirmation of skull maturity.
    Documentation Required

    Baseline Anti-AAV2 Antibody Testing

    Submit baseline laboratory results demonstrating that the anti-AAV2 neutralizing antibody titer or ELISA result meets policy criteria.

    • Anti-AAV2 neutralizing antibody titer must be < 1200 fold, or ELISA optical density must be > 1.
    Documentation Required

    Pregnancy Verification Before Administration

    For females with reproductive potential, verify and document negative pregnancy status before KEBILIDI administration.

    • There are no clinical data regarding KEBILIDI use during pregnancy or lactation.
    • Pregnancy verification is required when applicable before administration.
    Denial Risk

    Skull Maturity Is Required

    Do not proceed unless skull maturity has been established by neuroimaging. Patients who have not achieved skull maturity are contraindicated.

    • Age of at least 16 months alone does not replace the neuroimaging requirement.
    • Failure to establish skull maturity may result in denial.
    Denial Risk

    Clinical Eligibility Not Met

    Coverage may be denied when clinical eligibility or required documentation is not met.

    • Denial risks include age below 16 months, age 65 years or older, unconfirmed AADC deficiency, failure to document two positive core diagnostic tests, or missing specialist involvement.
    • Denial may also result when persistent neurological impairment despite standard medical therapy, skull maturity, or other required documentation is not established.
    Denial Risk

    Dose Exceeds Policy Limit

    The administered dose must not exceed 1.8 × 1011 vector genomes or 0.32 mL total volume.

    • A dose or total volume above the policy maximum may be denied.
    • KEBILIDI is supplied as a single-dose vial for intraputaminal administration only.
    Billing Rule

    Lifetime Dose Limit

    KEBILIDI is approved as a one-time treatment, with a maximum of one dose per lifetime.

    • Do not request or administer repeat treatment.
    • Total approval duration is one-time approval only.
    Denial Risk

    Baseline Antibody Requirement

    Document the baseline anti-AAV2 antibody result before treatment and confirm that it meets the policy threshold.

    • Required result: anti-AAV2 neutralizing antibody titer < 1200 fold or ELISA optical density > 1.
    • A missing result or a result that does not meet the applicable threshold may result in denial.
    Genetic diagnosis shows compound heterozygous or homozygous disease-causing variants in the DDC gene.
    Core Diagnostic Testing
    Genetic testingGenetic testing should be completed to confirm AADC deficiency.
    Confirmation thresholdTwo of the three core diagnostic tests must be positive.
    Core diagnostic toolsCSF neurotransmitter metabolite testing, genetic testing, and plasma AADC enzyme activity testing
    Age and anatomy: The patient is at least 16 months old and has achieved skull maturity documented by neuroimaging.≥16 months
    Antibody testing: Baseline anti-AAV2 neutralizing antibody titer is below 1200-fold or ELISA optical density is greater than 1.<1200-fold or OD >1
    Dose limit: The dose does not exceed 1.8 × 10^11 vector genomes or 0.32 mL total volume.1.8 × 10^11 vector genomes; 0.32 mL